A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing-Reference-Cited by-同舟云学术

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Published:2007-02-01 Issue:3 Volume:13 Page:986-993
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Fracasso Paula M.,Burris Howard,Arquette Matthew A.,Govindan Ramaswamy,Gao Feng,Wright Lisa P.,Goodner Sherry A.,Greco F. Anthony,Jones Suzanne F.,Willcut Noel,Chodkiewicz Catherine,Pathak Amit,Springett Gregory M.,Simon George R.,Sullivan Daniel M.,Marcelpoil Raphaël,Mayfield Shelley D.,Mauro David,Garrett Christopher R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies;mAbs;2024-03-04

2. Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer;Clinical Colorectal Cancer;2023-12

3. Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022;Bulletin du Cancer;2023-12

4. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies;British Journal of Clinical Pharmacology;2023-05

5. A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood;Immunological Investigations;2022-10-27